Although the study was well done, there are some limitations. As the authors acknowledge, the sample size was small, and the study was not therefore designed to assess the clinical benefits or risks of β2-adrenergic therapy. Also, we do not know whether the postoperative pulmonary edema was cardiogenic, noncardiogenic, or perhaps a combination of both etiologies in some patients. Similarly, improvements in both cardiac index and alveolar fluid clearance induced by salbutamol may contribute to the improvement in oxygenation demonstrated with β2-adrenergic therapy. In addition, as the authors recognize, the thermal method for measurement of extravascular lung water has potential methodologic issues, especially in terms of altered perfusion to edematous lung zones.10 Nevertheless, the results are both impressive and remarkably consistent with those of previous experimental and clinical studies5,8 documenting the impact of β2-agonist therapy on pulmonary edema.